Behavioral Activation Plus Low Vision Rehab Beneficial in AMD

Share this content:
Behavioral Activation Plus Low Vision Rehab Beneficial in AMD
Behavioral Activation Plus Low Vision Rehab Beneficial in AMD

MONDAY, March 20, 2017 (HealthDay News) -- Behavioral activation (BA) plus low vision rehabilitation with an occupational therapist (OT-LVR) is more effective than conventional low vision optometry services for patients with age-related macular degeneration (AMD), according to a study published in the March issue of Investigative Ophthalmology & Visual Science.

Ashley D. Deemer, O.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a randomized clinical trial involving 188 AMD patients with subsyndromal depressive symptoms. Participants had two outpatient low vision rehabilitation optometry visits and were randomly allocated to in-home BA + OT-LVR, which aimed to increase adaptive behaviors and achieve valued goals, or supportive therapy (ST), which is a nondirective, psychological treatment that provides emotional support. The active inventory was used to assess functional vision at baseline and four months in terms of goals and corresponding tasks.

The researchers found that both the BA + OT-LVR and ST groups had improvement in functional vision measures at the goal level. Compared with ST patients, BA + OT-LVR patients showed more improvement in reading, inside-the-home tasks, and outside-the-home tasks, at the task level. Subjects with a visual acuity of ≥20/70 had the greatest effects in the BA + OT-LVR group.

"BA + OT-LVR services, provided by an OT in the patient's home following conventional low vision optometry services, are more effective than conventional optometric low vision services alone for those with mild visual impairment," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »